TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19101456
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B virus (HBV) control vaccine
Study: 10715924
Drug: Continued aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continued aspirin therapy (100 mg daily)
Study: 10715924
Drug: Stopped aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stopped aspirin therapy (1 week before procedure)
Study: 1584314
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) treatment at 300 U/kg body weight i.v. once a week for 3 months
Study: 1584314
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) treatment and Control group
Study: 3156621
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dexamethasone given pre- and post-operatively
Study: 29727404
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg·kg)
Study: 29727404
Drug: p-Synephrine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: p-Synephrine (3 mg·kg)
Study: 29727404
Drug: p-Synephrine +
Normalized name: synephrine
DrugBank: Synephrine (DB09203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: p-Synephrine + Caffeine (3 mg·kg each)
Study: 24456716
Drug: Lutonix DCB
Normalized name: DCB
DrugBank: Dichlorobenzene (DB14046)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutonix DCB (2 μg/mm² paclitaxel)
Study: 15868230
Drug: No anti-adhesion
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-adhesion treatment (control)
Study: 11932569
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO3) ingestion (0.3 g.kg‐1 body mass)
Study: 9798800
Drug: UDCA 20
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 20 mg/kg/day
Study: 9128317
Drug: Bismuth-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-based triple therapy (BTM): bismuth subnitrate 75 mg q.i.d., oxytetracycline 500 mg q.i.d., metronidazole 400 mg b.i.d. for 14 days
Study: 9128317
Drug: Omeprazole-based triple
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole-based triple therapy (OAM): omeprazole 20 mg b.i.d., amoxicillin 750 mg b.i.d., metronidazole 400 mg b.i.d. for 14 days
Study: 9128317
Drug: Bismuth-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-based triple therapy (BTM) in nonrandomized group with metronidazole-resistant strains
Study: 9128317
Drug: Omeprazole-based triple
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole-based triple therapy (OAM) in nonrandomized group with metronidazole-resistant strains
Study: 7054901
Drug: Limb-sparing surgery
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limb-sparing surgery plus radiation therapy plus chemotherapy
Study: 7054901
Drug: Amputation plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amputation plus chemotherapy
Study: 30650266
Drug: Fusidic Acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic Acid Cream (FAC) alone for mild acne (39 cases)
Study: 30650266
Drug: Fusidic Acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic Acid Cream (FAC) combined with minocycline hydrochloride for severe acne (64 cases)
Study: 30650266
Drug: Longzhu Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longzhu Ointment (LO) alone for mild acne (27 cases)
Study: 30650266
Drug: Longzhu Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longzhu Ointment (LO) combined with minocycline hydrochloride for severe acne (56 cases)
Study: 30650266
Drug: Fusidic Acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic Acid Cream (FAC)
Study: 30650266
Drug: Longzhu Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longzhu Ointment (LO)
Study: 30650266
Drug: Fusidic Acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic Acid Cream (FAC) and Longzhu Ointment (LO)
Study: 21116645
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 45% ethanol and 18% 1-propanol with skin protecting ingredients (Softa-Man®)
Study: 21116645
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (with and without additives)
Study: 11506402
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) 2.0 g/kg given over one to two days
Study: 11506402
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone tapering from 60 mg to 10 mg daily over six weeks
Study: 9420037
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) 250 mg
Study: 9420037
Drug: Rifampin (RIF)
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (RIF) 600 mg
Study: 9420037
Drug: Pyrazinamide (PZA)
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyrazinamide (PZA) 1500 mg
Study: 8493625
Drug: BRL 38227
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRL 38227 (0.125, 0.25, and 0.5 mg)
Study: 8493625
Drug: BRL 38227
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRL 38227 (0.125 and 0.5 mg)
Study: 8493625
Drug: BRL 38227
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRL 38227 (0.5 mg)
Study: 3104624
Drug: Praziquantel at
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel at a dose of 40 mg kg‐1
Study: 3104624
Drug: Metrifonate at
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate at 10 mg kg‐1 (three fortnightly doses)
Study: 3104624
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of metrifonate
Study: 3104624
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metrifonate (10 mg kg‐1) and niridazole (25 mg kg‐1)
Study: 3104624
Drug: Reduced doses
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced doses of praziquantel
Study: 3104624
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metrifonate (10 mg kg‐1) and praziquantel (10 mg kg‐1)
Study: 27923057
Drug: Iron fortified
Normalized name: INFANT FORMULA SMA IRON FORTIFIED PWD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron fortified cereal supplement (FG)
Study: 27923057
Drug: Meat-based complementary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meat-based complementary food (MG)
Study: 27923057
Drug: Local cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local cereal supplement (LG)
Study: 24462043
Drug: 100 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g/d of white fish (Namibia hake) with advice on a healthy diet
Study: 20470283
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 mg daily for 2 months
Study: 18331436
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid supplementation (6 g/day containing 160 mg of eicosapentaenic acid and 100 mg of docosahexaenoic acid)
Study: 14696018
Drug: Milnacipran 50
Normalized name: milnacipran 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran 50 mg twice a day plus pindolol 2.5 mg three times a day
Study: 14696018
Drug: Milnacipran 50
Normalized name: milnacipran 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran 50 mg twice a day plus placebo three times a day
Study: 8601365
Drug: ibuprofen, 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen, 1600 mg/day
Study: 1987534
Drug: 12% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12% sucrose solution (2 mL) prior to blood collection
Study: 6344181
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sustained release tablet containing norephedrine
Study: 25100891
Drug: Electromagnetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electromagnetic therapy (administered once a day for 1 hour for 8 weeks)
Study: 14668578
Drug: Ticlopidine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 500 mg twice daily
Study: 11772700
Drug: Fluoxetine (N=24)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (N=24)
Study: 26520216
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) in combination with Treatment as Usual (TAU)
Study: 21315215
Drug: 3,000-U anti-Xa
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,000-U anti-Xa certoparin once daily
Study: 18996639
Drug: Vitamin B
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B therapy (group B)
Study: 16427339
Drug: High-dose pulse-spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pulse-spray thrombolysis (rt-PA, 15 mg/h for 2h)
Study: 16427339
Drug: Low-dose infusion
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose infusion (rt-PA, 0.5 mg/h for 48 h)
Study: 16427339
Drug: High-dose pulse-spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pulse-spray thrombolysis
Study: 19945274
Drug: Low-dose infusion
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose infusion
Study: 10718829
Drug: Diluted ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diluted ethanol (0.45 g ethanol/kg b.w.)
Study: 10718829
Drug: Water (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (150 ml doses)
Study: 1401653
Drug: Terfenadine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (300 mg)
Study: 17390144
Drug: Balsalazide 2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balsalazide 2.25 g daily for 10 days every month plus VSL#3 450 billions/day for 15 days every month
Study: 15668539
Drug: fosamprenavir/RTV 700/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: fosamprenavir/RTV 700/100 mg (arm B)
Study: 15668539
Drug: LPV/RTV/fosamprenavir 400/100/700
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/RTV/fosamprenavir 400/100/700 mg (arm C)
Study: 15668539
Drug: LPV/RTV 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/RTV 400/100 mg (arm A)
Study: 7636540
Drug: Dexverapamil (escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexverapamil (escalated from 240 to 1,200 mg/m2/d) combined with EPOCH chemotherapy
Study: 7636540
Drug: EPOCH chemotherapy
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPOCH chemotherapy alone
Study: 345414
Drug: Methylated analogues
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylated analogues of prostaglandin E2 administered orally
Study: 26429629
Drug: ORALMENT (L-menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORALMENT (L-menthol oral administration)
Study: 26429629
Drug: SKINMENT (L-menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKINMENT (L-menthol skin administration)
Study: 26429629
Drug: ORALCON (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORALCON (control for oral administration)
Study: 26429629
Drug: SKINCON (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKINCON (control for skin administration)
Study: 23883424
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL syringe
Study: 23883424
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL syringe
Study: 23883424
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL syringe
Study: 16643233
Drug: 1.5 mg/ml
Normalized name: thymol 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/ml levobupivacaine via CEI (15 mg/h)
Study: 16643233
Drug: 5 mg/ml
Normalized name: urea 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/ml levobupivacaine via CEI (15 mg/h)
Study: 16643233
Drug: 1.5 mg/ml
Normalized name: thymol 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/ml levobupivacaine via PCEA (5 mg bolus, 20 min lockout)
Study: 16643233
Drug: 5 mg/ml
Normalized name: urea 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/ml levobupivacaine via PCEA (5 mg bolus, 20 min lockout)
Study: 15292626
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of cognitive-behavioral therapy and ethyl loflazepate (2 mg daily) for 6 weeks
Study: 15292626
Drug: Antianxiety agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antianxiety agent only (ethyl loflazepate) for 6 weeks
Study: 15292626
Drug: Medication only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication only group
Study: 11321637
Drug: Self-study of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-study of chess positions (500 positions over several months, 15-30 minutes daily)
Study: 3323852
Drug: Sequential oestrogen/progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential oestrogen/progestogen therapy (4 mg, 2 mg, and 1 mg 17 beta‐oestradiol combined with 1 mg norethisterone acetate)
Study: 26777721
Drug: Real-time daily
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time daily patient feedback to providers along with provider coaching and revisits of patients not reporting optimal satisfaction with their care.
Study: 25178594
Drug: Azithromycin at
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin at a dose of 10mg/kg/day for 7 days
Study: 25178594
Drug: Cefixime at
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefixime at a dose of 20mg/kg/day in two divided doses for 14 days
Study: 20463186
Drug: RTX 2
Normalized name: RTX
DrugBank: Resiniferatoxin (DB06515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTX 2 x 500 mg
Study: 20463186
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation (2 x 500 mg to 2 x 1000 mg)
Study: 20463186
Drug: RTX 2
Normalized name: RTX
DrugBank: Resiniferatoxin (DB06515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTX 2 x 1000 mg
Study: 16855773
Drug: Korean Red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean Red Ginseng (KRG) 1,000 mg (3 times daily)
Study: 16163531
Drug: Bupropion (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (150 mg SR)
Study: 16163531
Drug: Methamphetamine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine (0, 15, and 30 mg)
Study: 10091831
Drug: i.c. adenosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.c. adenosine (2.4 mg/min for 10 min starting 20 min before the first occlusion)
Study: 7594412
Drug: Thiazide diuretics
Normalized name: althiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretics or beta-blockers (first- or second-line drugs)
Study: 7594412
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of diastolic hypertension
Study: 7594412
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of isolated systolic hypertension
Study: 28577292
Drug: Teneligliptin 20
Normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Teneligliptin 20 mg/day for 12 weeks
Study: 20204975
Drug: Full intervention
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full intervention (peer-modelling materials, daily pedometer goals, rewards)
Study: 20204975
Drug: No-rewards intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-rewards intervention (peer-modelling materials, daily pedometer goals, no rewards)
Study: 20204975
Drug: No-rewards intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-rewards intervention (after taper phase)
Study: 20204975
Drug: Full intervention
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full intervention (after taper phase)
Study: 19751560
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment without low-dose hydrocortisone)
Study: 17299470
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of oral riboflavin and other B-group vitamins daily for 14 days
Study: 2839538
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg iv bolus dose of methoxamine
Study: 30457655
Drug: Monthly ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monthly ranibizumab dosing
Study: 30457655
Drug: Treat-and-extend (T&E)
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treat-and-extend (T&E) ranibizumab dosing
Study: 25764996
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment for 1 year in infants (m/f: 11/8)
Study: 25764996
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment for 2 years in prepubertal children (m/f: 14/14)
Study: 24092509
Drug: Propofol/remifentanil intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol/remifentanil intravenous anaesthesia
Study: 21045734
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with amlodipine/valsartan 10/320 mg (after dose increase at week 2) and hydrochlorothiazide 12.5 mg (added at week 4)
Study: 21045734
Drug: Moderate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate treatment with amlodipine/valsartan 5/160 mg and hydrochlorothiazide 12.5 mg (added at week 4)
Study: 21045734
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with amlodipine/valsartan 10/320 mg and hydrochlorothiazide 12.5 mg
Study: 21045734
Drug: Moderate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate treatment with amlodipine/valsartan 5/160 mg and hydrochlorothiazide 12.5 mg
Study: 8695601
Drug: Polysaccharide-free diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysaccharide-free diet with breakfast supplement (biscuits made from wheat, potato, or banana flours; moist-heat-processed wheat or maize flours)
Study: 23128847
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AT and EMS (AT+EMS)
Study: 22320418
Drug: Latanoprost 0.005%/timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 0.005%/timolol maleate 0.5% fixed combination (LTFC)
Study: 22320418
Drug: Dorzolamide hydrochloride
Normalized name: Dorzolamide Hydrochloride
DrugBank: Dorzolamide (DB00869)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dorzolamide hydrochloride 2%/timolol maleate 0.5% fixed combination (DTFC)
Study: 21145518
Drug: Stretching treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretching treatment performed by physical therapists
Study: 21145518
Drug: Stretching treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretching treatment performed by parents
Study: 15640320
Drug: CRQ-Self-Administered (CRQ-SA)
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CRQ-Self-Administered (CRQ-SA)
Study: 15640320
Drug: CRQ-Interviewer Administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRQ-Interviewer Administered (CRQ-IA)
Study: 8792352
Drug: Opsite 3000TM
Normalized name: DRESSING,OPSITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opsite 3000TM (transparent moisture vapor permeable dressings, MVPD) changed weekly
Study: 24506274
Drug: Anesthetic gel
Normalized name: Topicaine 4% Topical Anesthetic Gel
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic gel (5% lidocaine and 5% prilocaine) applied in the sulcus 5 minutes before the procedure
Study: 24506274
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no anesthetic gel)
Study: 20694407
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day of PUFAs
Study: 18405951
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 mcg (for patients aged < 11 years) or 400 mcg once daily
Study: 12053591
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (two puffs four times daily, 0.002 g/puff)
Study: 8519669
Drug: Primary treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary treatment: debulking surgery followed by platinum-based chemotherapy
Study: 27663942
Drug: Treatment responders
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment responders from the acute trial